L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 227.9 ILS -14.13% Market Closed
Market Cap: 114.6m ILS
Have any thoughts about
Lineage Cell Therapeutics Inc?
Write Note

Wall Street
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 786.94 ILS with a low forecast of 1 415.54 ILS and a high forecast of 2 575.29 ILS.

Lowest
Price Target
1 415.54 ILS
521% Upside
Average
Price Target
1 786.94 ILS
684% Upside
Highest
Price Target
2 575.29 ILS
1 030% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
VICO
Vicore Pharma Holding AB
281% Upside
BIIB
Biogen Inc
59% Upside
688373
Shanghai MicuRx Pharmaceutical Co Ltd
39% Upside
BLAU3
Blau Farmaceutica SA
22% Upside
OCX
OncoCyte Corp
55% Upside
TNGX
Tango Therapeutics Inc
223% Upside
RCUS
Arcus Biosciences Inc
132% Upside
1952
Everest Medicines Ltd
21% Downside

Revenue
Forecast

Revenue Estimate
Lineage Cell Therapeutics Inc

For the last 8 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 3%. The projected CAGR for the next 3 years is 42%.

3%
Past Growth
42%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LCTX's stock price target?
Price Target
1 786.94 ILS

According to Wall Street analysts, the average 1-year price target for LCTX is 1 786.94 ILS with a low forecast of 1 415.54 ILS and a high forecast of 2 575.29 ILS.

What is Lineage Cell Therapeutics Inc's Revenue forecast?
Projected CAGR
42%

For the last 8 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 3%. The projected CAGR for the next 3 years is 42%.

Back to Top